

SUPPLEMENTAL MATERIAL

Supplemental Tables

Supplemental Table S1. Attributes for the evaluated serologic assays as given by the manufacturers' package inserts.

Attribute	Elecsys CoV-2	Anti-SARS-CoV-2	SARS-CoV-2 IgG	SARS-CoV-2 (COV2T)	total	SARS-CoV-2 (COV2G)	IgG
Manufacturer	Roche		Abbott	Siemens	Siemens		
Version of the package insert	July 2020		April 2020	Mai 2020	June 2020		
CE-IVD status	Conform		Conform	Conform	Conform		
EUA status	Granted		Granted	Granted	Granted		
Method	ECLIA		CMIA	CLIA	CLIA		
Platform	Cobas e411, e601, e602 ^a , e801		ARCHITECT i2000SR ^a , i1000SR	ADVIA Centaur XP ^a , XPT	ADVIA Centaur XP ^a , XPT		
Specimen type	Serum, plasma (Li-heparin, K-EDTA)		Serum, plasma (EDTA)	Serum, plasma (Li-heparin, K-EDTA)	Serum, plasma (Li-heparin, K-EDTA)		
Sample volume (without dead volume)	20 µl		25 µl	50 µl	10 µl		
Detected antibodies	Total antibodies, including IgG		IgG	Total antibodies, including IgG and IgM	IgG		
Solid-phase antigen target	N protein		N protein	RBD of the S1 protein	RBD of the S1 protein		
Result calculation	Cut-off index		Index (S/Co)	Index	Index		
Interpretation	<1,0: negative ≥1,0: positive		<1,4: negative ≥1,4: positive	<1,0: negative ≥1,0: positive	<1,0: negative ≥1,0: positive		
Diagnostic specificity*	99.80% (99.69-99.88%). n=10,432		99.63% (98.98-99.89%). n=1,066	99.81% (99.41-99.96%). n=1,589	99.89% (99.61-99.99%). n=1,831		
Diagnostic sensitivity*	<i>Days after first PCR-positivity</i>		<i>Days after symptom onset</i>	<i>Days after first PCR-positivity</i>	<i>Days after first PCR-positivity</i>		
	0-6: 60.20% (52.30-67.80%). n=161		<3: 0.00% (0.00-60.24%). n=4	0-6: 61.05% (50.50-70.89%). n=95	0-6: 53.49% (42.41-64.23%). n=86		
	7-13: 85.30% (78.60-90.60%). n=150		3-7: 25.00% (3.19-65.09%). n=8	7-13: 97.50% (92.87-99.48%). n=120	7-13: 93.44% (84.05-98.18%). n=61		
	≥14: 99.50% (97.00-100.00%). n=185		8-13: 86.36% (65.09-97.09%). n=22	≥14:100.00% (92.45-100.00%). n=47	≥14:100.00% (91.59-100.00%). n=42		
			≥14:100.00% (95.89-100.00%). n=88				
Accuracy	Within-day: 1.3-2.8% Between-day: 2.2-7.2%		Within-day: 1.1-5.9% Between-day: 1.2-5.9%	Within-day: 2.6-10.8% Between-day: 5.2-12.4%	Within-day: 2.0-4.6% Between-day: 2.8-6.1%		

In brackets 95% confidence intervals are shown. Abbreviations: CE-IVD, European Conformity - In Vitro Diagnostic Medical Device; CLIA, chemiluminescence immunoassay; CMIA, chemiluminescent microparticle immunoassay; ECLIA, electrochemiluminescence immunoassay; ELISA, enzyme-linked immunosorbent assay; EUA: Emergency Use Authorization; K, potassium; Li, Lithium; n: number of samples tested; RBD: receptor-binding domain; S/Co, signal-to-cutoff ratio. ^a indicates the platform used in our study.

Supplemental Table S2. Diagnostic specificity of the four assays.

Assay	Total	Negative	Positive	Specificity
Roche Elecsys Anti-SARS-CoV-2	341	340	1	99.71% (98.38-99.99%)
Abbott SARS-CoV-2 IgG	298	296	2	99.33% (97.60-99.92%)
Siemens SARS-CoV-2 total (COV2T)	288	287	1	99.65% (98.08-99.99%)
Siemens SARS-CoV-2 IgG (COV2G)	191	191	0	100.00% (98.09-100.00%)

Specificity of the assays was determined on 350 pre-pandemic samples; 95% confidence intervals are given in brackets.

Supplemental Table S3. False positive results in pre-pandemic samples.

Sample number	Roche SARS-CoV-2	Elecsys	Anti-	Abbott SARS-CoV-2 IgG	Siemens SARS-CoV-2 total (COV2T)	Siemens SARS-CoV-2 IgG (COV2G)
1	n	0.08	p	1.46	n	0.13
2	p	1.18	n	0.04		
3	n	0.09	p	2.42	n	0.21
4	n	0.09			p	2.91
					n	0.17
					n	0.04

Individual results (assay index) of all samples tested positive in at least one assay of 350 pre-pandemic samples are shown. Positive results (p) are shown in red, negative results (n) are shown in green.

Supplemental Table S4. Measurements of the immunoglobulin formulation Privigen®, undiluted and 1:50 diluted.

Privigen	Roche Elecsys Anti-SARS-CoV-2	Abbott SARS-CoV-2 IgG	Siemens SARS-CoV-2 total (COV2T)	Siemens SARS-CoV-2 IgG (COV2G)
Undiluted	0.14	0.65	<0.05	1.09
1:50, negative serum	0.08	0.01	<0.05	0.01
1:50, sodium chloride	0.15	0.05	0.26	0.23

Data indicate the respective results of the raw data indexes of the tests. Privigen® was diluted with negative pre-pandemic serum or sodium chloride, respectively.

Supplemental Table S5. Individual results of all 230 sensitivity samples.

#	#	Disease course	Days	Roche SARS-CoV-2	Elecsys	Anti-SARS-CoV-2	Abbott SARS-CoV-2 IgG	Siemens SARS-CoV-2 total (COV2T)	Siemens SARS-CoV-2 IgG (COV2G)
1	1	outpatient	16	p	4.42	p	4.81		
2	2	outpatient	20	p	4.46	p	4.24		
3	3	outpatient	21	p	19.93	p	6.92	p	6.50
4	4	outpatient	24	p	24.56	p	6.72	p	>10.00
5	5	outpatient	25	p	17.66	p	1.49		
6	6	outpatient	25	p	5.32	p	3.85		
7	7	outpatient	27	p	26.00	p	4.80	p	>10.00
8	8	outpatient	30	p	3.82	p	3.05	p	1.58
9	9	outpatient	30	p	46.16	p	9.15		
10	10	outpatient	32	p	2.86	n	0.71	p	4.07
11	11	outpatient	32	p	3.00	p	1.78	p	6.14
12	12	outpatient	33	p	30.01	p	4.68	p	3.63
13	13	outpatient	34	n	0.24	n	0.03	n	0.29
14	14	outpatient	36	p	28.47	p	4.96	p	4.84
15	15	outpatient	38	p	8.58	p	3.10	p	2.55
16	16	outpatient	38	n	0.11	n	0.01		
17	17	outpatient	39	p	38.64	p	7.68	p	>10.00
18	18	outpatient	39	p	43.54	p	5.66	p	3.86
19	19	outpatient	40	p	13.36	p	2.45	p	>10.00
20	20	outpatient	40	p	84.46	p	7.99	p	>10.00
21	21	outpatient	42	p	4.58	p	2.52		

22	22	outpatient	42	p	32.47	p	4.04				
23	23	outpatient	43	p	88.73	p	8.67	p	>10.00	p	6.75
24	24	outpatient	43	n	0.11	n	0.18	n	<0.05	n	0.04
25	25	outpatient	45	p	92.52	p	6.79	p	1.98	p	1.86
26	26	outpatient	45	p	39.48	p	9.90	p	7.36	p	6.76
27	27	outpatient	46	p	108.40	p	7.56	p	9.68	p	1.11
28	28	outpatient	47	p	14.35	p	2.29	p	2.48	n	0.15
29	29	outpatient	47	p	144.40	p	3.94	p	9.11	p	1.80
30	30	outpatient	48	p	58.86	p	6.18	p	>10.00	p	9.86
31	31	outpatient	48	p	9.34	p	2.64	p	3.12	n	0.39
32	32	outpatient	48	p	31.36	p	5.13	p	3.38	n	0.50
33	33	outpatient	48	p	68.75	p	6.04	p	1.35	p	1.08
34	34	outpatient	49	p	29.76	p	2.31	p	>10.00	p	1.86
35	35	outpatient	49	p	33.96	p	4.70	n	0.87	n	0.45
36	36	outpatient	49	n	0.11	n	0.30	n	0.28	n	0.10
37	37	outpatient	50	p	47.36	p	6.32	p	7.65	p	1.86
38	38	outpatient	50	p	27.04	p	3.93	p	7.76	n	0.62
39	39	outpatient	51	p	67.02	p	6.94	p	>10.00	p	5.97
40	40	outpatient	51	p	69.06	p	9.11	p	9.79	p	2.53
41	41	outpatient	52	p	37.19	p	6.63	p	5.94	n	0.88
42	42	outpatient	52	p	12.66	p	3.18	p	2.33	n	0.55
43	43	outpatient	53	p	45.49	p	4.17	p	3.50	p	1.45
44	44	outpatient	55	n	0.09	n	0.07	n	0.40	n	0.12
45	45	outpatient	55	p	198.00	p	5.73	p	8.16	p	2.84
46	46	outpatient	56	p	20.74	n	1.23			n	0.37
47	47	outpatient	57	p	85.05	p	9.21	p	>10.00	p	16.47
48	48	outpatient	58	p	69.65	p	5.16	p	1.08	n	0.22
49	49	outpatient	58	p	88.64	p	9.55	p	>10.00	p	1.37
50	50	outpatient	58	p	49.01	p	5.58	p	3.62	n	0.64
51	51	outpatient	59	p	50.49	p	4.64	p	>10.00	p	1.34
52	52	outpatient	59	p	37.06	p	4.50	p	4.45	p	1.67
53	53	outpatient	59	p	68.29	p	5.98	p	>10.00	p	3.51
54	54	outpatient	60	p	7.79	p	2.66	p	2.86	n	0.53
55	55	outpatient	61	p	13.53	p	1.53	p	2.59	p	1.34
56	56	outpatient	61	p	45.69	p	4.23	n	0.27	n	0.28
57	57	outpatient	61	p	77.00	p	8.41	p	>10.00	p	>20.00
58	58	outpatient	62	p	229.00	p	9.10	p	>10.00	p	5.83
59	59	outpatient	64	p	23.78	p	7.16	p	1.95	p	3.73
60	60	outpatient	64	p	24.67	p	4.25	p	5.82	n	0.44
61	61	outpatient	65	p	122.10	p	6.40	p	9.17	p	1.03
62	62	outpatient	65	p	51.98	p	5.67	p	5.97	n	0.57
63	63	outpatient	65	p	3.15	n	0.70	p	1.54	n	0.21
64	64	outpatient	66	p	15.00	p	2.79	p	>10.00	p	1.12
65	65	outpatient	68	n	0.09	n	0.02	n	0.13	n	0.07
66	66	outpatient	69	p	28.61	p	2.16	p	7.83	p	2.17
67	67	outpatient	70	p	1.52	n	0.84	p	1.27	n	0.22
68	68	outpatient	71	p	209.50	p	6.20	p	9.04	p	2.00

69	69	outpatient	71	p	97.84	p	3.59	p	9.45	p	2.53
70	70	outpatient	72	p	53.74	p	3.54	p	>10.00	p	2.09
71	71	outpatient	72	p	13.01	n	0.87	p	5.62	p	1.15
72	72	outpatient	75	n	0.11	n	0.02	n	0.11	n	0.03
73	73	outpatient	77	p	18.45	p	3.46	p	6.68	p	1.14
74	74	outpatient	77	p	149.40	p	9.26	p	>10.00	p	12.18
75	75	outpatient	82	p	215.30	p	3.58	p	>10.00	p	1.12
76	76	outpatient	82	p	163.90	p	7.97				
77	77	outpatient	85	p	159.60	p	6.16	p	>10.00	p	2.38
78	78	outpatient	87	p	126.50	p	3.04	p	5.54	n	0.89
79	79	outpatient	89	p	159.00	p	2.73	p	>10.00	p	1.12
80	80	outpatient	90	p	153.00	p	6.37	p	6.93	p	3.95
81	81	outpatient	90	p	212.20	p	7.67	p	4.28	p	1.31
82	82	outpatient	97	p	194.20	p	4.53	p	>10.00	p	6.43
83	83	outpatient	104	p	51.14	p	2.06				
84	84	outpatient	111	p	72.73	p	3.70				
85	85	outpatient	120	p	93.09	p	3.61				
86	1	general ward	14	p	15.79	p	4.55	p	>10.00	p	7.58
87	2	general ward	14	p	8.29	p	5.80	p	8.52	p	1.74
88	3	general ward	14	p	8.53	p	6.61	p	4.99	p	17.86
89	4	general ward	14	n	0.47	n	0.94	n	0.34	n	0.12
90	5	general ward	14	p	3.56	p	3.14	p	>10.00	n	0.45
91	6	general ward	14	p	3.25	p	6.66				
92	7	general ward	14	p	5.27	p	4.02				
93	8	general ward	15	p	10.91	p	3.63	p	>10.00	p	5.67
94	9	general ward	15	p	27.00	p	4.74	p	9.13	p	2.47
95	10	general ward	15	p	15.63	p	4.70	p	3.42	n	0.24
96	11	general ward	15	p	24.61	p	8.39	p	>10.00	p	10.50
97	12	general ward	15	p	45.55	p	8.27	p	>10.00	p	>20.00
98	13	general ward	15	p	1.65	p	3.93				
99	14	general ward	15	p	13.66	p	1.87				
100	15	general ward	16	p	14.70	p	8.47	p	>10.00	p	14.47
101	16	general ward	16	p	11.99	p	6.45	p	>10.00	p	9.65
102	17	general ward	16	p	18.97	n	0.78	p	>10.00	p	>20.00
103	18	general ward	17	p	3.50	p	5.96	p	>10.00	p	1.85
104	19	general ward	17	p	3.71	p	5.69	p	>10.00	p	7.32
105	20	general ward	17	p	14.37	p	8.71	p	2.55	p	3.42
106	21	general ward	17	p	52.97	p	8.96	p	>10.00	p	>20.00
107	22	general ward	17	p	25.00	p	7.05	p	7.06	p	11.61
108	23	general ward	17	p	15.84	p	4.97				
109	24	general ward	17	p	1.43						
110	25	general ward	18	p	19.79	p	2.08	p	>10.00	p	2.66
111	26	general ward	18	p	11.51	p	7.59	p	>10.00	p	16.18
112	27	general ward	18	p	21.65	p	8.25	p	>10.00	p	14.52
113	28	general ward	19	p	19.30	p	8.08	p	>10.00	p	15.71
114	29	general ward	19	n	0.25	p	8.30	n	0.67	n	0.03
115	30	general ward	19	n	0.18	n	0.08	p	1.75	n	0.53

116	31	general ward	19	p	9.95	p	5.98	p	>10.00	p	6.80
117	32	general ward	19	p	37.50	p	6.12	p	>10.00	p	>20.00
118	33	general ward	20	p	4.02	p	3.38	p	>10.00	p	8.24
119	34	general ward	20	p	22.21	p	7.05	p	>10.00	p	>20.00
120	35	general ward	20	p	5.84	p	1.84	n	0.68	n	0.29
121	36	general ward	20	p	13.03	p	6.69			p	3.80
122	37	general ward	20	p	9.58	p	4.86				
123	38	general ward	21	p	1.15	p	5.28	n	0.29	n	0.50
124	39	general ward	21	p	36.54	p	7.18	p	>10.00	p	16.86
125	40	general ward	21	p	21.26	p	6.13	p	>10.00	p	>20.00
126	41	general ward	21	p	13.90	p	5.50	p	>10.00	p	11.43
127	42	general ward	22	p	39.78	p	8.90	p	>10.00	p	5.74
128	43	general ward	23	p	33.15	p	8.25	p	>10.00	p	>20.00
129	44	general ward	23	p	21.92	p	8.16	p	>10.00	p	>20.00
130	45	general ward	24	p	44.42	p	2.25	p	5.83	p	1.68
131	46	general ward	24	n	0.80	p	6.47	p	>10.00	p	10.70
132	47	general ward	24	p	14.02	p	7.35	p	>10.00	p	14.59
133	48	general ward	24	p	39.26	p	9.46	p	>10.00	p	6.44
134	49	general ward	24	p	41.21	p	8.50	p	>10.00	p	>20.00
135	50	general ward	25	p	35.27	p	8.70	p	>10.00	p	>20.00
136	51	general ward	26	p	9.41	p	6.88	p	>10.00	p	>20.00
137	52	general ward	27	p	12.94	p	8.00	p	>10.00	p	9.12
138	53	general ward	28	p	15.53	p	8.83	p	>10.00	p	6.44
139	54	general ward	28	p	3.23	p	5.91	p	>10.00	p	>20.00
140	55	general ward	28	p	35.48	p	8.77	p	>10.00	p	8.24
141	56	general ward	33	p	60.67	p	6.60			p	14.07
142	57	general ward	34	p	84.65	p	8.00	p	>10.00		
143	58	general ward	39	p	70.82	p	9.50				
144	59	general ward	44	p	86.18	p	8.53	p	>10.00	p	4.46
145	60	general ward	46	p	87.75	p	6.27	p	>10.00	p	5.15
146	61	general ward	46	p	53.67	p	7.24	p	>10.00	p	4.82
147	62	general ward	46	p	95.25	p	9.12				
148	63	general ward	47	p	75.33	p	6.05	p	>10.00	p	5.16
149	64	general ward	48	p	64.57	p	7.68	p	>10.00	p	16.59
150	65	general ward	49	p	14.45	p	4.60	p	>10.00	p	2.60
151	66	general ward	50	n	0.09	n	0.01	n	0.19	n	0.03
152	67	general ward	50	p	63.92	p	6.15	p	>10.00	p	>20.00
153	68	general ward	50	n	0.32	n	0.69	n	0.10	n	0.93
154	69	general ward	51	p	51.54	p	8.63	p	>10.00	p	6.90
155	70	general ward	51	p	47.70	p	6.30	p	2.73	p	1.01
156	71	general ward	53	p	15.11	p	7.84	n	0.75	p	1.43
157	72	general ward	54	p	19.18	p	8.44	p	>10.00	p	7.18
158	73	general ward	54	p	66.68	p	8.18	p	>10.00	p	4.95
159	74	general ward	57	p	76.02	p	7.48	p	>10.00	p	4.90
160	75	general ward	58	p	70.55	p	7.95	p	>10.00	p	>20.00
161	76	general ward	58	p	3.94	n	1.35	p	2.78	n	0.54
162	77	general ward	58	p	36.85	p	3.64				

163	78	general ward	59	p	50.29	p	2.53	n	0.36	n	0.55
164	79	general ward	59	p	98.70	p	9.02	p	>10.00	p	3.13
165	80	general ward	59	p	42.36	p	7.14	p	>10.00	p	>20.00
166	81	general ward	60	p	53.45	p	7.65				
167	82	general ward	61	p	49.65	p	6.58	p	>10.00	p	7.04
168	83	general ward	61	p	210.10	p	7.34	p	9.51	p	1.97
169	84	general ward	61	p	64.63	p	3.42	p	>10.00		
170	85	general ward	62	p	92.64	p	7.43	p	>10.00	p	8.49
171	86	general ward	62	p	16.23	p	2.50	p	7.66	p	2.05
172	87	general ward	63	n	0.10	n	0.04	n	<0.05	n	0.07
173	88	general ward	63	p	84.20	p	9.44	p	>10.00	p	7.20
174	89	general ward	63	p	60.58	p	9.03	p	>10.00	p	6.47
175	90	general ward	63	p	94.06	p	8.45	p	>10.00	p	>20.00
176	91	general ward	65	p	161.80	p	8.39	p	5.91	p	2.84
177	92	general ward	65	p	139.40	p	7.02	p	>10.00	p	4.39
178	93	general ward	67	p	70.86	p	5.13	p	>10.00	p	4.91
179	94	general ward	68	p	36.67	p	3.42	p	2.87	n	0.87
180	95	general ward	69	p	71.77	p	9.45	p	>10.00	p	4.72
181	96	general ward	70	p	80.46	p	5.26	p	1.87	n	0.33
182	97	general ward	71	p	81.51	p	4.53	p	>10.00	p	>20.00
183	98	general ward	71	p	92.71	p	9.59	p	5.57	p	2.79
184	99	general ward	71	p	131.20	p	7.04	p	>10.00	p	10.69
185	100	general ward	71	p	141.40	p	8.91	p	>10.00	p	11.69
186	101	general ward	72	p	178.50	p	7.33	p	>10.00	p	19.26
187	102	general ward	73	p	85.78	p	9.28	p	>10.00		
188	103	general ward	74	p	71.67	p	8.98	p	>10.00	p	18.08
189	104	general ward	96	p	104.10	p	7.02				
190	105	general ward	107	p	106.40	p	7.50				
191	106	general ward	108	p	17.44	p	1.56				
192	1	intensive care	18	p	17.25	p	7.01	p	>10.00	p	16.86
193	2	intensive care	19	p	68.42	p	8.86	p	>10.00	p	7.03
194	3	intensive care	21	p	26.31	p	8.42	p	>10.00	p	>20.00
195	4	intensive care	21	p	9.31	p	6.68	p	>10.00	p	10.95
196	5	intensive care	21	p	43.80	p	8.02	p	>10.00	p	3.41
197	6	intensive care	21	p	47.57	p	4.40				
198	7	intensive care	23	p	1.35	p	7.65	p	>10.00	p	1.86
199	8	intensive care	24	p	52.95	p	9.54	p	>10.00	p	>20.00
200	9	intensive care	24	p	47.73	p	8.03	p	>10.00	p	>20.00
201	10	intensive care	25	p	75.09	p	8.76	p	>10.00	p	7.59
202	11	intensive care	26	p	28.22	p	8.70	p	>10.00	p	>20.00
203	12	intensive care	26	p	77.10	p	8.63	p	>10.00	p	>20.00
204	13	intensive care	27	p	11.43	p	7.59	p	>10.00	p	8.59
205	14	intensive care	27	p	38.86	p	8.60	p	>10.00	p	14.35
206	15	intensive care	28	p	5.54	p	7.70	p	>10.00	p	5.21
207	16	intensive care	28	p	10.13	p	6.24	p	>10.00	p	7.25
208	17	intensive care	28	p	39.27	p	7.61	p	>10.00	p	>20.00
209	18	intensive care	28	p	7.43	n	1.36	p	2.74		

210	19	intensive care	28	p	6.42	p	4.99	p	>10.00	p	>20.00
211	20	intensive care	28	p	52.77	p	8.17	p	>10.00	p	13.39
212	21	intensive care	28	p	23.44	p	8.40	p	>10.00	p	19.09
213	22	intensive care	29	p	75.52	p	9.26	p	>10.00	p	>20.00
214	23	intensive care	31	p	16.55	p	8.30	p	>10.00	p	6.73
215	24	intensive care	31	p	70.01	p	8.76	p	>10.00	p	>20.00
216	25	intensive care	31	p	72.69	p	8.99	p	>10.00	p	>20.00
217	26	intensive care	31	p	77.61	p	8.34	p	>10.00	p	>20.00
218	27	intensive care	34	n	0.08	n	0.01	n	0.20	n	0.13
219	28	intensive care	35	n	0.11			n	<0.05		
220	29	intensive care	40	p	77.42	p	9.29				
221	30	intensive care	41	p	58.18	p	7.68	p	>10.00	p	7.46
222	31	intensive care	65	p	44.20	p	4.77				
223	32	intensive care	66	p	117.50	p	8.01	p	>10.00	p	19.63
224	33	intensive care	67	p	191.60	p	8.63	p	>10.00	p	9.48
225	34	intensive care	78	p	94.79	p	4.24	p	>10.00	p	>20.00
226	35	intensive care	80	p	84.76	p	6.06	p	>10.00		
227	36	intensive care	84	p	88.00	p	8.24	p	>10.00	p	>20.00
228	37	intensive care	87	p		p	8.76				
229	38	intensive care	98	p	105.70	p	8.90				
230	39	intensive care	99	p	73.59	p	8.74				

Individual results (raw data assay index) of the samples of SARS-CoV-2 PCR-confirmed patients are shown (one sample per patient; the sample ≥ 14 days and closest to day 28 after symptom onset was used). Positive results (p) are shown in red, negative results (n) are shown in green. Days indicate the time between disease onset and blood sampling. # indicates the patient number.

Supplemental Table S6. Diagnostic sensitivity of the four assays stratified for disease course, age and gender.

		Roche SARS-CoV-2	Elecsys Anti-SARS-CoV-2	Abbott SARS-CoV-2 IgG	Siemens SARS-CoV-2 total (COV2T)	Siemens SARS-CoV-2 IgG (COV2G)
Sensitivity according to PI		99.50% (97.00-100.00%)		100.00% (95.89-100.00%)	100.00% (92.45-100.00%)	100.00% (91.59-100.00%)
All patients	Total		230	229		195
	Positive		214	208		176
	Negative		16	21		19
	Sensitivity	93.04% (88.95-95.97%)		90.83% (86.32-94.23%)		90.26% (85.20-94.03%)
Outpatient	Total		85	85		72
	Positive		78	73		64
	Negative		7	12		8
	Sensitivity	91.76% (83.77-96.62%)		85.88% (76.64-92.49%)		88.89% (79.28-95.08%)
Gen. ward	Total		106	105		90
	Positive		99	98		81
	Negative		7	7		9
	Sensitivity	93.40% (86.87-97.30%)		93.33% (86.75-97.28%)		90.00% (81.86-95.32%)
ICU	Total		39	38		33
	Positive		37	36		31
	Negative		2	2		2
	Sensitivity	94.87% (82.68-99.37%)		94.74% (82.25-99.36%)		93.94% (79.77-99.26%)
18-49	Total		74	73		60
	Positive		70	63		53
	Negative		4	10		7
	Sensitivity	94.59% (86.73-98.51%)		86.30% (76.25-93.23%)		88.33% (77.43-95.18%)
50-69	Total		109	109		97
	Positive		102	101		91
	Negative		7	8		6
	Sensitivity	93.58% (87.22-97.83%)		92.66% (86.05-96.78%)		93.81% (87.02-97.70%)
70-100	Total		47	46		38
	Positive		42	43		32
	Negative		5	3		6
	Sensitivity	89.36% (76.90-96.45%)		93.48% (82.10-98.63%)		84.21% (68.75-93.98%)
Male	Total		147	146		129
	Positive		140	138		120
	Negative		7	8		9
	Sensitivity	95.24% (90.43-98.06%)		94.52% (89.49-97.60%)		93.02% (87.17-96.76%)
Female	Total		83	82		66
	Positive		74	69		56
	Negative		9	13		10
	Sensitivity	89.16% (80.41-94.92%)		84.15% (74.42-91.28%)		84.85% (73.90-92.49%)

Sensitivity of the evaluated test-systems including all SARS-CoV-2 PCR-confirmed patients (one sample per patient; the sample ≥ 14 days and closest to day 28 after symptom onset was used) and stratified for severity of the disease (outpatient, hospitalised at the general ward, hospitalized at the intensive care unit) as well as age (18-49, 50-69, 70-100 years), respectively. 95% confidence intervals are given in brackets. Abbreviations: PI: package insert.

Supplemental Table S7. Positivity rate across the time course of the disease.

Roche Elecsys Anti-SARS-CoV-2		Abbott SARS-CoV-2 IgG		Siemens SARS-CoV-2 total (COV2T)		Siemens SARS-CoV-2 IgG (COV2G)		
days	n	Positivity rate	n	Positivity rate	n	Positivity rate	n	Positivity rate
0-6	43	25,58% (13.25-41.17%)	41	19,51% (8.82-34.87%)	28	32,14% (15.88-52.35%)	27	22,22% (8.62-42.26%)
7-13	114	52,63% (43.06-62.06%)	113	53,98% (44.35-63.40%)	97	54,64% (44.21-64.78%)	96	40,62% (30.71-51.13%)
14-20	107	91,59% (84.63-96.08%)	107	95,33% (89.43-98.47%)	95	88,42% (80.23-94.08%)	94	80,85% (71.44-88.24%)
21-40	122	90,98% (84.44-95.41%)	117	91,45% (84.84-95.83%)	109	90,83% (83.77-95.51%)	101	91,09% (83.76-95.84%)
>40	309	90,29% (86.43-93.35%)	306	89,87% (85.93-93.01%)	188	87,77% (82.21-92.08%)	180	77,78% (70.99-83.62%)

A total of 700 samples of 245 SARS-CoV-2 PCR-confirmed patients were measured. The table shows the positivity rate of the four investigated assays depending on the time course of the disease. Days indicate the time between disease onset and blood sampling. N indicates the total number of samples tested. 95% confidence intervals are given in brackets.

Supplemental Table S8. ROC curve analysis of the four assays.

Assay	AUC
Roche Elecsys Anti-SARS-CoV-2	0.984 (0.974-0.991)
Abbott SARS-CoV-2 IgG	0.982 (0.970-0.990)
Siemens SARS-CoV-2 total (COV2T)	0.975 (0.961-9.986)
Siemens SARS-CoV-2 IgG (COV2G)	0.966 (0.948-0.980)

ROC curve analysis was based on 350 pre-pandemic (=negative) samples (samples, Roche: 341, Abbott: 298, Siemens COV2T: 288, Siemens COV2G: 191) and the samples of SARS-CoV-2 PCR-confirmed (=positive) patients (samples, Roche: 537, Abbott: 530, Siemens COV2T: 392, Siemens COV2G: 375). Samples of SARS-CoV-2 positive patients were only considered if time-span between disease onset and blood draw was ≥ 14 days. 95% confidence intervals are given in brackets. Abbreviations: AUC, area under the curve; ROC, receiver operating characteristic.

Supplemental Table S9. Sensitivity and specificity of the assays using the modified cut-off index.

		Manufacturer's COI	Modified COI
Roche Elecsys Anti-SARS-CoV-2	COI	≥1.0: positive	>0.15: positive
	Sensitivity (n=230)	93.04% (89.00-95.67%)	95.65% (92.18-97.62%)
	Specificity (n=341)	99.71% (98.36-99.95%)	97.36% (95.06-98.61%)
Abbott SARS-CoV-2 IgG	COI	≥1.4: positive	>0.54: positive
	Sensitivity (n=228)	90.79% (86.33-93.90%)	95.18% (91.57-97.28%)
	Specificity (n=298)	99.33% (97.59-99.82%)	98.32% (96.13-99.28%)
Siemens SARS-CoV-2 total (COV2T)	COI	≥1.0: positive	>0.42: positive
	Sensitivity (n=195)	90.26% (85.28-93.67%)	92.31% (87.70-95.28%)
	Specificity (n=288)	99.65% (98.06-99.94%)	98.61% (96.48-99.46%)
Siemens SARS-CoV-2 IgG (COV2G)	COI	≥1.0: positive	>0.32: positive
	Sensitivity (n=193)	78.76% (72.45-83.94%)	89.64% (84.54-93.19%)
	Specificity (n=191)	100.00% (98.03-100.00%)	97.38% (94.02-98.88%)




Sensitivity and specificity of the assays using different cut-off indexes (COI): the COI according to the manufacturer and a modified COI according to our ROC curve analysis. Sensitivity was evaluated on samples of SARS-CoV-2 PCR-confirmed patients (one sample per patient; the sample ≥14 days and closest to day 28 after symptom onset was used). Specificity was determined on 350 pre-pandemic samples. 95% confidence intervals are shown in brackets.

Supplemental Table S10. Concordance correlation coefficient between the four assays.


Test	Roche	Abbott	Siemens COV2T	Siemens COV2G
Roche	x	90.13 (n=972)	92.49 (n=800)	81.93 (n=689)
Abbott		x	85.47 (n=750)	77.45 (n=645)
Siemens COV2T			x	84.93 (n=680)

Concordance correlation coefficient of the qualitative results of the four assays (350 pre-pandemic samples and all 700 samples of SARS-CoV-2 PCR-confirmed patients). Abbreviations: n, total number of samples measured with both assays. Abbott = Abbott SARS-CoV-2 IgG; Roche = Roche Elecsys Anti SARS-CoV-2; Siemens COV2G = Siemens SARS-CoV-2 IgG; Siemens COV2T = Siemens SARS-CoV-2 Total.

Supplemental Figures



Supplemental Figure S1. Distribution of sample timing. Horizontal axis: time span between disease onset and timing of the blood draw of the sample used for the sensitivity analysis. Vertical axis: number of samples. A) all patients; B) outpatient; C) hospitalized patients (general ward and intensive care unit, ICU).



Supplemental Figure S2. Raw data index results of all 700 samples of SARS-CoV-2 PCR-confirmed patients, stratified for the time course of the disease. Horizontal axis: days after symptom onset. Vertical axis: raw data index of the respective test. Dashed horizontal line: manufacturer's cut-off index. Solid horizontal line: modified cut-off index.